Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
B.1.177.6NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.560ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.560ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.560NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.560NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.560NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-19391.8China
B.1.610ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.610ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.610NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.610NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-2491.68Singapore
B.1.610NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
AY.10 (Delta)ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
AY.10 (Delta)ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
AY.10 (Delta)NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
AY.10 (Delta)NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
AY.10 (Delta)NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.2ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.177.2ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.2NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.2NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.286ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.1.286ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.286NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.286NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.286NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.36.17ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.36.17ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.36.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.36.17NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.36.17NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.1.369ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.1.369ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.1.369NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.1.369NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.1.369NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.69ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.177.69ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.69NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.69NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.69NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.8ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.177.8ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.8NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
B.1.177.8NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
B.1.177.8NChan-NGCGTTCTTCGGAATGTCG1855.562921029227F-21207.6China
B.1.177.26ORF1abPasteur-ORF1ab-1ATGAGCTTAGTCCTGTTG1844.441269012707F-17837.6France
B.1.177.26ORF1abPasteur-ORF1ab-1CTCCCTTTGTTGTGTTGT1844.441279712780R-18837.8France
B.1.177.26NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-1668.53US
B.1.177.26NYoung-NAGCACCATAGGGAAGTCC1855.562864828631R-19874.5Singapore
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used